ArticleBiology2021
Comparison of Epidermal Barrier Integrity in Adults with Classic Atopic Dermatitis, Atopic Prurigo and Non-Atopic Prurigo Nodularis.
Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- TRPM8 Agonist (Cryosim-1) Cream for Chronic Prurigo: A Randomized, Vehicle-controlled Trial.Acta dermato-venereologica · 2025Trial
- Long-term Progressive Improvement of Atopic Dermatitis by an Herbal Emollient Plus Combination in a 12-week Clinical Trial.Acta dermato-venereologica · 2025Trial
- Observational
- A murine model of prurigo nodularis-like skin lesions induced by persistent scratching under type 2 inflammatory conditions.Frontiers in immunology · 2025Article
- Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.The Journal of dermatology · 2024Article
- A Novel Epidermis Model Using Primary Hidradenitis Suppurativa Keratinocytes.Journal of tissue engineering and regenerative medicine · 2024Article
- Atopic Dermatitis Across Shades of Skin.American journal of clinical dermatology · 2023Review
- The Acari Hypothesis, III: Atopic Dermatitis.Pathogens (Basel, Switzerland) · 2022Article
- Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.Dermatology and therapy · 2022Review
- Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series.Acta dermato-venereologica · 2022Article
- Thalidomide Responsive Recalcitrant Adult-Onset Atopic Dermatitis - Repurposing an Old Drug.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A deficient epidermal barrier is a key feature of atopic dermatitis (AD) and comprises altered lipid and protein content and composition of the stratum corneum resulting in disturbed water balance. Clinically, eczematous lesions on dry skin and pruritus develop. Pruritic nodules occur in prurigo nodularis (PN), another chronic skin disease, which can be associated with atopy. We aimed at comparing the three clinical pictures, classic AD, atopic prurigo (AP), and non-atopic PN, to healthy controls regarding the epidermal barrier. We determined clinical parameters and performed biophysical measurements, histology/immunohistochemistry, electron microscopy, and molecular biological analysis. We found distinctively elevated clinical scores, reduced hydration and increased transepidermal water loss, epidermal hyperplasia and inflammation reduced filaggrin and increased loricrin and involucrin expression, as well as reduced intercellular lipid lamellae in all three disease groups. These findings show a severe disruption in epidermal barrier structure and function in all three disorders so that epidermal barrier impairment is now proven not only for AD but also for PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.